SG11202111076WA - Therapeutic rna for ovarian cancer - Google Patents

Therapeutic rna for ovarian cancer

Info

Publication number
SG11202111076WA
SG11202111076WA SG11202111076WA SG11202111076WA SG11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA SG 11202111076W A SG11202111076W A SG 11202111076WA
Authority
SG
Singapore
Prior art keywords
ovarian cancer
therapeutic rna
rna
therapeutic
ovarian
Prior art date
Application number
SG11202111076WA
Inventor
Ugur Sahin
David Weber
Carina Walter
Roldan Diana Barea
Ruprecht Kuner
Meike Wagner
Martin Suchan
Maurici Stefania Gangi
Stefanie Hubich-Rau
René Becker
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Publication of SG11202111076WA publication Critical patent/SG11202111076WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
SG11202111076WA 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer SG11202111076WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019062967 2019-05-20
PCT/EP2020/064180 WO2020234410A1 (en) 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer

Publications (1)

Publication Number Publication Date
SG11202111076WA true SG11202111076WA (en) 2021-11-29

Family

ID=67587718

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111076WA SG11202111076WA (en) 2019-05-20 2020-05-20 Therapeutic rna for ovarian cancer

Country Status (14)

Country Link
US (1) US20220257631A1 (en)
EP (1) EP3972632A1 (en)
JP (1) JP2022533717A (en)
KR (1) KR20220010500A (en)
CN (1) CN114051412A (en)
AU (1) AU2020277683A1 (en)
CA (1) CA3140496A1 (en)
CL (1) CL2021003063A1 (en)
CO (1) CO2021016301A2 (en)
CU (1) CU20210097A7 (en)
IL (1) IL287554A (en)
MX (1) MX2021014226A (en)
SG (1) SG11202111076WA (en)
WO (1) WO2020234410A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112501201A (en) * 2021-02-07 2021-03-16 无锡市人民医院 RNA vaccine for treating non-small cell lung cancer and construction method thereof
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
TW202333802A (en) * 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2014298504B2 (en) * 2013-07-30 2018-08-30 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences

Also Published As

Publication number Publication date
EP3972632A1 (en) 2022-03-30
WO2020234410A1 (en) 2020-11-26
CO2021016301A2 (en) 2022-04-08
AU2020277683A1 (en) 2021-11-04
CA3140496A1 (en) 2020-11-26
CU20210097A7 (en) 2022-06-06
CL2021003063A1 (en) 2022-10-14
KR20220010500A (en) 2022-01-25
MX2021014226A (en) 2022-01-06
CN114051412A (en) 2022-02-15
US20220257631A1 (en) 2022-08-18
JP2022533717A (en) 2022-07-25
IL287554A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
SG10201913631TA (en) Rna for cancer therapy
IL287554A (en) Therapeutic rna for ovarian cancer
ZA202005847B (en) Cancer therapy
SG11202101397TA (en) Biomarkers for cancer therapy
IL287907A (en) Methods for treating cancer
ZA202106392B (en) Therapeutic rna for prostate cancer
GB201905780D0 (en) Cancer therapy
GB201903546D0 (en) Cancer treatment
IL292272A (en) Cancer vaccine
EP3713576A4 (en) Methods for cancer therapy
IL282093A (en) Combination therapy for cancer
IL287652A (en) Cancer treatment
IL285466A (en) Cancer treatment
GB201909468D0 (en) Compounds for treating cancer
GB2580963B (en) Cancer therapies
IL286353A (en) Combinations of iadademstat for cancer therapy
IL288035A (en) Cancer treatment
IL284646A (en) Therapeutic rna for advanced stage solid tumor cancers
IL286680A (en) Medicament for treating cancer
GB201913957D0 (en) Cancer
EP3981473A4 (en) Therapeutic agent for cancer
EP3847282A4 (en) Biomarkers for cancer therapy
EP3597197A4 (en) Novel technique for treating cancer using structurally-reinforced s-tud
EP3344287A4 (en) Anti-survivin antibodies for cancer therapy
GB201901368D0 (en) Cancer therapy